91843-27-5

Basic information

• Product Name: 3-PYRIDINEACETIC ACID, 6-METHYL-,ETHYL ESTER
• Synonyms: 3-PYRIDINEACETIC ACID, 6-METHYL-,ETHYL ESTER;ETHYL (6-METHYLPYRIDIN-3-YL)ACETATE;Ethyl 2-(6-Methylpyridin-3-Yl)Acetate;Ethyl (6-methyl-3-pyridinyl)acetate;(6-METHYLPYRIDIN-3-YL)ACETIC ACID ETHYL ESTER
• CAS NO: 91843-27-5
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.22
• Mol File: 91843-27-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-PYRIDINEACETIC ACID, 6-METHYL-,ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PYRIDINEACETIC ACID, 6-METHYL-,ETHYL ESTER(91843-27-5)
• EPA Substance Registry System: 3-PYRIDINEACETIC ACID, 6-METHYL-,ETHYL ESTER(91843-27-5)

Safety Data

• Hazardous Substances Data: 91843-27-5(Hazardous Substances Data)

Usage

General Description

3-Pyridineacetic acid, 6-methyl-, ethyl ester is a chemical compound with the molecular formula C10H13NO2. It is a methylated ester derivative of 3-pyridineacetic acid and is commonly used in organic synthesis and as a building block in the pharmaceutical industry. It has a molecular weight of 179.21 g/mol and is a colorless to pale yellow liquid with a fruity odor. It is primarily used as an intermediate in the synthesis of various pharmaceutical compounds and can also be used as a fragrance ingredient in personal care products. 3-Pyridineacetic acid, 6-methyl-, ethyl ester is also used in the manufacturing of agrochemicals, insecticides, and herbicides.

Upstream product

• 19733-96-1 2-(6-methylpyridin-3-yl)acetic acid 
• 64-17-5 ethanol 
• 36357-38-7 1-(6-methyl-pyridin-3-yl)-ethanone 
• 5552-83-0 ethyl 2-(6-methylpyridin-2-yl)acetate 

Relevant articles and documents

Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia

Small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) are currently under clinical development as novel treatment options for chronic kidney disease (CKD) associated anemia. Inhibition of HIF-PH mimics hypoxia and leads to increased erythropoietin (EPO) expression and subsequently increased erythropoiesis. Herein we describe the discovery, synthesis, structure–activity relationship (SAR), and proposed binding mode of novel 2,4-diheteroaryl-1,2-dihydro-3H-pyrazol-3-ones as orally bioavailable HIF-PH inhibitors for the treatment of anemia. High-throughput screening of our corporate compound library identified BAY-908 as a promising hit. The lead optimization program then resulted in the identification of molidustat (BAY 85-3934), a novel small-molecule oral HIF-PH inhibitor. Molidustat is currently being investigated in clinical phase III trials as molidustat sodium for the treatment of anemia in patients with CKD.

N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases

The present invention describes compounds of formula I and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The formula I compounds are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for examp